Nephrogen
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies includ
Y Combinator
yc-company-directory #1670Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies includ
sourceTechstars
techstars-portfolio #1523Nephrogen is a biotech company developing curative gene therapies for kidney and pancreatic diseases.
sourceNephrogen is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Nephrogen
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Pando Bioscience
match 89Pando is an AI-driven synthetic biology company revolutionizing enzyme engineering for the pharmaceutical industry. Our ultra-high-throughput screening platform screens 1000-fold more enzymes 75% faster and 80% cheaper than traditional methods. This empowers our generative AI to efficiently optimize enzymes across multiple properties, delivering high-performing, tailored enzymes that reduce costs and enhance efficiency.
shared extracted concept terms: high, throughput, screen, pharmaceutical; shared product terms: high, throughput, screen, engineer; shared product theme: context and memory; same category: AI infrastructure; shared affiliation: Y Combinator
Arpeggio Bio
match 72Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
shared extracted concept terms: high, throughput; shared product terms: pharmaceutical, develop, high, throughput; same category: AI infrastructure; shared affiliation: Y Combinator
Biolinco
match 71Biolinco develops an AI-enabled, high-throughput cell line screening platform for biopharmaceutical manufacturers to efficiently identify optimal cell lines using DNA barcoding technology, addressing the issue of low-yielding cell lines
shared extracted concept terms: high, throughput, screen; shared product terms: develop, high, throughput, screen; shared product theme: context and memory; same category: AI infrastructure; shared affiliation: Techstars
Rosebud Biosciences
match 56Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already
shared extracted concept terms: companie; shared product terms: stanford, disease, gene, screen; shared product theme: context and memory; shared affiliation: Y Combinator
Perlara
match 56Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clin
shared extracted concept terms: companie; shared product terms: out, disease, gene, screen; shared product theme: context and memory; shared affiliation: Y Combinator
Turntable
match 54Turntable allows less technical analysts to build their own data pipelines. Companies use our AI-native workspace to scale their analytics without hiring more engineers. If you use DBT or Airflow- or you're building out your data stack for the first time- please reach out!
shared extracted concept terms: companie; shared product terms: out, engineer, less, reach; same category: AI infrastructure; shared affiliation: Y Combinator